Related Experiment Videos
[Neuroglycopenic syndromes in malignant tumors]
1Interné odd. A, KUNZ B. Bystrica.
Vnitrni Lekarstvi
|October 1, 1990
Summary
Malignant tumors can cause spontaneous hypoglycemia through three main mechanisms: liver damage, IGF II production by mesenchymal tumors, or insular tumors/nesidioblastomas. These mechanisms impact glycogen, insulin, and growth hormone regulation.
Area of Science:
- Endocrinology
- Oncology
Background:
- Spontaneous hypoglycemia can be a rare but serious complication of malignancy.
- Understanding the underlying mechanisms is crucial for diagnosis and management.
Observation:
- Analysis of five patients with malignant tumors presenting with hypoglycemia.
- Observed varying clinical and biochemical profiles associated with different tumor types.
Findings:
- Mechanism 1: Liver metastases impair glycogenolysis and counter-regulatory hormone effectiveness.
- Mechanism 2: Large mesenchymal tumors associated with neoplastic Insulin-like Growth Factor II (IGF II) production, characterized by low C-peptide, immunoreactive insulin (IRI), blunted growth hormone response, and elevated IGF II.
- Mechanism 3: Metastatic insular tumors or nesidioblastomas causing hypoglycemia with high IRI and C-peptide, often accompanied by peptic ulcers due to gastrin production.
Implications:
- Differentiates hypoglycemia causes in cancer patients, aiding targeted treatment.
- Highlights the role of IGF II in tumor-induced hypoglycemia.
- Suggests specific tumor markers and clinical features for diagnosing the cause of hypoglycemia in malignancy.